RxDoctor Payments Data

Lisandra Perez Colon, MD

Pulmonary Disease · Ponce, PRNPI 1942206115

Payments from drug & device makers

$2,667in general payments, 2019–2025

Across 94 payments — averaging $28.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$993
  • AstraZeneca$512
  • Sanofi$419
  • Boehringer Ingelheim$203
  • Takeda Pharmaceuticals U.S.A., Inc.$138
  • United Therapeutics Corporation$136
  • plus $265 from 8 others

What the payments were for

  • Food & beverage$2,63299%
  • Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,667 in reported general payments places this provider in the 50th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$4,292
Medicare patients
22
Services billed
48

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate52$680,739
AdempasRiociguat41$569,598
Dupixent PenDupilumab100$379,052
Trelegy ElliptaFluticasone/Umeclidin/Vilanter525$353,895
OpsumitMacitentan24$302,740
Spiriva RespimatTiotropium Bromide421$230,070
Atrovent HfaIpratropium Bromide377$182,493
NucalaMepolizumab25$92,314
Dupixent SyringeDupilumab19$71,089
Combivent RespimatIpratropium/Albuterol Sulfate141$70,984
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate264$67,732
Arnuity ElliptaFluticasone Furoate187$54,703
Albuterol Sulfate HfaAlbuterol Sulfate1,211$48,990
Breztri AerosphereBudesonide/Glycopyr/Formoterol74$48,032
SymbicortBudesonide/Formoterol Fumarate157$40,254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat$203$988,533628 claims
BayerAdempas$18$569,59841 claims
GSKTrelegy Ellipta, Nucala, Arnuity Ellipta, Breo Ellipta$993$539,518830 claims
AstraZenecaBreztri Aerosphere, Symbicort$512$88,286231 claims
MerckDulera$61$3,81911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →